In vivo validation of late-onset Alzheimer's disease genetic risk factors
dc.contributor.author | Sasner, Michael | |
dc.contributor.author | Preuss, Christoph | |
dc.contributor.author | Pandey, Ravi S. | |
dc.contributor.author | Uyar, Asli | |
dc.contributor.author | Garceau, Dylan | |
dc.contributor.author | Kotredes, Kevin P. | |
dc.contributor.author | Williams, Harriet | |
dc.contributor.author | Oblak, Adrian L. | |
dc.contributor.author | Lin, Peter Bor-Chian | |
dc.contributor.author | Perkins, Bridget | |
dc.contributor.author | Soni, Disha | |
dc.contributor.author | Ingraham, Cindy | |
dc.contributor.author | Lee-Gosselin, Audrey | |
dc.contributor.author | Lamb, Bruce T. | |
dc.contributor.author | Howell, Gareth R. | |
dc.contributor.author | Carter, Gregory W. | |
dc.contributor.department | Radiology and Imaging Sciences, School of Medicine | |
dc.date.accessioned | 2024-05-22T11:39:32Z | |
dc.date.available | 2024-05-22T11:39:32Z | |
dc.date.issued | 2023-12-24 | |
dc.description.abstract | Introduction: Genome-wide association studies have identified over 70 genetic loci associated with late-onset Alzheimer's disease (LOAD), but few candidate polymorphisms have been functionally assessed for disease relevance and mechanism of action. Methods: Candidate genetic risk variants were informatically prioritized and individually engineered into a LOAD-sensitized mouse model that carries the AD risk variants APOE4 and Trem2*R47H. Potential disease relevance of each model was assessed by comparing brain transcriptomes measured with the Nanostring Mouse AD Panel at 4 and 12 months of age with human study cohorts. Results: We created new models for 11 coding and loss-of-function risk variants. Transcriptomic effects from multiple genetic variants recapitulated a variety of human gene expression patterns observed in LOAD study cohorts. Specific models matched to emerging molecular LOAD subtypes. Discussion: These results provide an initial functionalization of 11 candidate risk variants and identify potential preclinical models for testing targeted therapeutics. | |
dc.eprint.version | Pre-Print | |
dc.identifier.citation | Sasner M, Preuss C, Pandey RS, et al. In vivo validation of late-onset Alzheimer's disease genetic risk factors. Preprint. bioRxiv. 2023;2023.12.21.572849. Published 2023 Dec 24. doi:10.1101/2023.12.21.572849 | |
dc.identifier.uri | https://hdl.handle.net/1805/40932 | |
dc.language.iso | en_US | |
dc.publisher | bioRxiv | |
dc.relation.isversionof | 10.1101/2023.12.21.572849 | |
dc.rights | Attribution 4.0 International | en |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
dc.source | PMC | |
dc.subject | APOE4 | |
dc.subject | Abca7 | |
dc.subject | Alzheimer’s disease | |
dc.subject | Animal models | |
dc.subject | Mthfr | |
dc.subject | Plcg2 | |
dc.subject | Preclinical | |
dc.subject | Transcriptomic analysis | |
dc.subject | Trem2 | |
dc.title | In vivo validation of late-onset Alzheimer's disease genetic risk factors | |
dc.type | Article |